A double-blind, controlled trial of bioflorin (Streptococcus faecium SF68) in adults with acute diarrhea due to Vibrio cholerae and enterotoxigenic Escherichia coli

The therapeutic efficacy of Bioflorin (Streptococcus faecium SF68; Gipharmex, Milan, Italy) in acute watery diarrhea was evaluated in 183 Bangladeshi adults. Vibrio cholerae organisms were isolated from stool cultures in 114 patients, and enterotoxigenic Escherichia coli organisms were isolated in 4...

Full description

Saved in:
Bibliographic Details
Published inGastroenterology (New York, N.Y. 1943) Vol. 99; no. 4; p. 1149
Main Authors Mitra, A K, Rabbani, G H
Format Journal Article
LanguageEnglish
Published United States 01.10.1990
Subjects
Adult
Antidiarrheals
Bacterial Vaccines - therapeutic use
Cholera - therapy
Diarrhea - etiology
Diarrhea - prevention & control
Double-Blind Method
Escherichia coli Infections - therapy
Humans
Male
Randomized Controlled Trials as Topic
Online AccessGet more information

Cover

More Information
Summary:The therapeutic efficacy of Bioflorin (Streptococcus faecium SF68; Gipharmex, Milan, Italy) in acute watery diarrhea was evaluated in 183 Bangladeshi adults. Vibrio cholerae organisms were isolated from stool cultures in 114 patients, and enterotoxigenic Escherichia coli organisms were isolated in 41. In addition to IV rehydration, patients were randomly assigned to receive either capsules of Bioflorin containing 1 X 10(9) of live SF68 or capsules of placebo containing killed SF68 once every 8 hours for 3 days. No other drugs were allowed during this period. Bioflorin was well tolerated. It is concluded that Bioflorin has no demonstrable antidiarrheal property in adults with acute diarrhea due to V. cholerae or enterotoxigenic E. coli infection.
ISSN:0016-5085
DOI:10.1016/0016-5085(90)90638-H